Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARIZ-PRDM2-siRNA
- Development stage
- Preclinical
- Lead developer
- ARIZ Precision Medicine
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
01
Overview
ARIZ-PRDM2-siRNA is an investigational siRNA-based cancer therapy being developed by ARIZ Precision Medicine for the treatment of liver cancer and other solid tumors. The drug utilizes small interfering RNA (siRNA) to knockdown the expression of PRDM2 (also known as RIZ), a member of the PRDM family of epigenetic regulators that act as genetic drivers for cell growth, proliferation, and survival. ARIZ delivers the siRNA using its proprietary ligand-targeted nanoparticle drug delivery system (T-DDS), which is designed to selectively target and destroy cancer cells while sparing healthy tissue. The program is currently in the preclinical stage, having demonstrated proof of principle in the T-DDS delivery system.
- Other names
- PRDM2-siRNA Liver Cancer ProgramPRDM-2-siRNA Liver Cancer ProgramPRDM 2-siRNA Liver Cancer ProgramARIZ Precision Medicine-PRDM2-siRNA-Liver Cancer
02
Targets
PRDM2 (PR domain zinc finger protein 2)
Beyond the preview
Go deeper on ARIZ-PRDM2-siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARIZ-PRDM2-siRNA.